Taking the LEAP: an evaluation of the compuLsive Exercise Activity Program (LEAP) in patients with eating disorders

Taking the LEAP: an effectiveness trial of the compuLsive Exercise Activity Program (LEAP) - a cognitive behavioural program specifically targeting compulsive exercise in patients with eating disorders

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN80711391

Enrollment

128

Registered

2020-03-25

Start date

2021-11-09

Completion date

Unknown

Last updated

2024-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Eating disorders Mental and Behavioural Disorders Eating disorders

Interventions

Current interventions as of 14/07/2021: Eligible patients are recruited in collaboration with eating disorder specialist treatment units. Patient consenting to participate will be assigned experimenta

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Current participant inclusion criteria as of 14/07/2021: 1. Male and female patients, =18 years of age 2. AN, BN or OSFED (Atypical AN, BN/Binge Eating Disorder with low frequency and/or limited duration of symptoms, and Purging Disorder) 3. Reporting CE at T1 (EDEQ item 27, see Instruments) 4. Entering outpatient care at a specialised ED treatment unit Previous participant inclusion criteria: 1. Male and female patients, =18 years of age 2. AN, BN or OSFED (Atypical AN and BN/Binge Eating Disorder with low frequency and/or limited duration of symptoms) 3. Reporting CE at T1 (EDEQ item 27, see Instruments) 4. Entering outpatient care at a specialised ED treatment unit

Exclusion criteria

Exclusion criteria: 1. Inability to communicate in Swedish 2. Psychotic disorder 3. High suicide risk 4. BMI<14

Design outcomes

Primary

Measure	Time frame
Current primary outcome measure as of 14/07/2021: 1. Eating disorder (ED) diagnosis measured by the Eating Disorder Examination (EDE) or the Structured Eating Disorder Interview (SEDI) at baseline and 6 months 2. ED cognitions measured by the Eating Disorder Examination Questionnaire (EDEQ) at baseline, 3, and 6 months 3. Compulsive Exercise measured by the Compulsive Exercise Test (CET) at baseline, 3, and 6 months 4. Body Mass Index (BMI) at baseline, 3, and 6 months 5. The difficulties in emotion regulation scale (DERS) at baseline, 3, and 6 months Previous primary outcome measure: Assessed initially and at 6-month follow-up (T3). All these outcome variables, except ED diagnosis, will also be assessed at the 3-month follow-up (T2): 1. Eating disorder (ED) diagnosis measured by the Structured Eating Disorder Interview 2. ED cognitions measured by the Eating Disorder Examination Questionnaire 3. Compulsive Exercise measured by the Compulsive Exercise Test	—

Measure

Time frame

Current primary outcome measure as of 14/07/2021: 1. Eating disorder (ED) diagnosis measured by the Eating Disorder Examination (EDE) or the Structured Eating Disorder Interview (SEDI) at baseline and 6 months 2. ED cognitions measured by the Eating Disorder Examination Questionnaire (EDEQ) at baseline, 3, and 6 months 3. Compulsive Exercise measured by the Compulsive Exercise Test (CET) at baseline, 3, and 6 months 4. Body Mass Index (BMI) at baseline, 3, and 6 months 5. The difficulties in emotion regulation scale (DERS) at baseline, 3, and 6 months Previous primary outcome measure: Assessed initially and at 6-month follow-up (T3). All these outcome variables, except ED diagnosis, will also be assessed at the 3-month follow-up (T2): 1. Eating disorder (ED) diagnosis measured by the Structured Eating Disorder Interview 2. ED cognitions measured by the Eating Disorder Examination Questionnaire 3. Compulsive Exercise measured by the Compulsive Exercise Test

—

Secondary

Measure	Time frame
Current secondary outcome measures as of 14/07/2021: 1. General psychopathology measured by the DSM-5 Self-Rated Level 1 Cross-Cutting Symptom Measure at baseline, 3, and 6 months 2. Active Q at baseline, 3, and 6 months 3. Patient rated treatment content (to control for potential efforts geared at CE in the TAU group) at baseline and 6 months 4. Feasibility and acceptability questionnaire (patient satisfaction with LEAP, only LEAP group) at baseline and 6 months Previous secondary outcome measures: Assessed initially and at 6-month follow-up (T3). All these outcome variables, except ED diagnosis, will also be assessed at the 3-month follow-up (T2): 1. Body Mass Index (BMI) 2. General psychopathology measured by the DSM-5 Self-Rated Level 1 Cross-Cutting Symptom Measure	—

Measure

Time frame

Current secondary outcome measures as of 14/07/2021: 1. General psychopathology measured by the DSM-5 Self-Rated Level 1 Cross-Cutting Symptom Measure at baseline, 3, and 6 months 2. Active Q at baseline, 3, and 6 months 3. Patient rated treatment content (to control for potential efforts geared at CE in the TAU group) at baseline and 6 months 4. Feasibility and acceptability questionnaire (patient satisfaction with LEAP, only LEAP group) at baseline and 6 months Previous secondary outcome measures: Assessed initially and at 6-month follow-up (T3). All these outcome variables, except ED diagnosis, will also be assessed at the 3-month follow-up (T2): 1. Body Mass Index (BMI) 2. General psychopathology measured by the DSM-5 Self-Rated Level 1 Cross-Cutting Symptom Measure

—

Countries

Sweden

Contacts

Public ContactEmma Forsén Mantilla

emma.forsen@ki.se+46 (0)736543254

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 14, 2026